health youth care inspectorate

What health youth care inspectorate does

The Health and Youth Care Inspectorate (IGJ), known in Dutch as Inspectie Gezondheidszorg en Jeugd, is the Dutch government supervisory authority responsible for safeguarding and enhancing the safety and quality of healthcare and youth care in the Netherlands. The IGJ operates as a statutory body under the Ministry of Health, Welfare and Sport (VWS), with its headquarters in Utrecht and is wholly owned by the Dutch government. The organization was established in its current form around 2017 and exercises regulatory authority over institutions, professionals, and producers across healthcare, youth care, and pharmaceuticals. It identifies the greatest risks in healthcare through supervision, conducts research on products and themes, investigates and handles reports, records complaints, and implements compliance measures.

The IGJ provides regulatory oversight across four main domains. In Medicines, it conducts Good Manufacturing Practice (GMP) inspections of pharmaceutical manufacturers (including facilities outside the EEA), supervises Good Distribution Practice (GDP) across the supply chain, performs pharmacovigilance inspections, manages quality defect reporting and recall coordination, and monitors illegal trade in medicines. In Medical Technology, it oversees market authorization for medical devices and IVDs under European MDR and IVDR regulations, conducts post-market surveillance supervision, manages vigilance and incident reporting, and supervises digital care/eHealth applications including telemedicine and medical apps. The National Authority for Containment (NAC) audits and certifies Poliovirus Essential Facilities under WHO's Global Action Plan for Poliovirus Containment (GAPIV). The IGJ also certifies Good Laboratory Practice (GLP) compliance. It holds statutory enforcement powers including administrative fines up to €450,000, product suspension orders, and criminal case referrals to the Public Prosecution Service.

The IGJ's business model is entirely non-commercial: it is funded by the Ministry of Health, Welfare and Sport and does not sell products or services. Its authority derives from Dutch statute and EU regulations. The IGJ participates in EU regulatory networks, coordinating with the European Medicines Agency (EMA), the Medical Device Coordination Group (MDCG), other EU member state inspection authorities, and the World Health Organization. Its digital infrastructure includes IGJ Rijkscloud for secure document exchange, ZIVVER encrypted email, and integration with EU databases including EUDAMED, EudraGMDP, and XEVMPD. In 2023, 801 pharmacovigilance questionnaires were sent to Marketing Authorization Holders (with 91% response rate), 24 authorized representatives were inspected in 2022-2023, and 4 Dutch notified bodies are currently designated for medical device certification.

Name

health youth care inspectorate

Legal name

Health and Youth Care Inspectorate

Website

https://english.igj.nl

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

The Health and Youth Care Inspectorate (IGJ) is a Dutch government regulatory authority under the Ministry of Health, Welfare and Sport, supervising pharmaceutical manufacturing, medical devices, healthcare, and youth care quality and safety in the Netherlands.

Ownership category

akta.pro rank

Product category

Healthcare Regulatory Supervision

NAICS

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615), Justice, Public Order, and Safety Activities (922)

akta.pro primary industry

Regulatory Compliance, Licensing & Enforcement (Public Health) (HLAJAMAE)

akta.pro secondary industries

Manufacturing Quality, GMP Inspections & Compliance (HLAJADAG), Healthcare Compliance & Enforcement Authorities (HLAJACAB), Healthcare Quality & Patient Safety Regulators (HLAJACAD), Drug Regulators (Human Pharmaceuticals) (HLAJADAA), Health Regulation, Licensing & Compliance (Public Health) (BPAIAJAN)

Keywords

• Healthcare regulation
• Pharmaceutical inspection
• Medical device oversight
• Youth care supervision
• GMP certification

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Distribution channels2 records

Marketing channels4 records

Core offering

The Health and Youth Care Inspectorate (IGJ) provides statutory regulatory oversight of healthcare, youth care, medicines, and medical devices in the Netherlands. It conducts GMP/GDP/pharmacovigilance inspections of pharmaceutical manufacturers, supervises medical device market authorisation under EU MDR/IVDR, monitors post-market surveillance and incident reporting, oversees digital care (eHealth) applications, and operates the National Authority for Containment (NAC) for poliovirus-essential facilities. It enforces compliance through administrative fines up to €450,000, product suspensions, and criminal referrals.

Product overview

The Health and Youth Care Inspectorate (IGJ) is a Dutch government regulatory body under the Ministry of Health, Welfare and Sport. It operates as a multi-module supervisory platform providing regulatory oversight across four main domains: (1) Medicines - covering GMP inspections, GDP distribution supervision, pharmacovigilance, quality defect reporting, and illegal trade monitoring; (2) Medical Technology - covering market authorisation, post-market surveillance, safety notices, and digital care/eHealth; (3) National Authority for Containment - poliovirus facility monitoring; and (4) Good Laboratory Practice (GLP) certification. The IGJ issues GMP certificates, supervises notified bodies for CE marking, manages recall systems, and coordinates with EU databases like EUDAMED and EudraGMDP. Its digital services include secure document exchange via IGJ Rijkscloud and secure email via ZIVVER.

Differentiator

Problem solved

Functional benefit

Products and services

• GMP Inspections and Certification Good Manufacturing Practice inspections of medicinal product manufacturers to verify compliance with international GMP quality assurance guidelines. Issues GMP certificates valid in all EEA countries. For pharmaceutical manufacturers, API producers, and manufacturing sites.
• GMP Inspections Outside Europe Inspection services for medicinal product manufacturing facilities located outside the European Economic Area (EEA) when products manufactured abroad enter the European market. Ensures European rules apply regardless of manufacturing location.
• Quality Defect Reporting and Recalls System for reporting quality defects of medicines on the market and coordinating recalls at patient, pharmacy, or wholesale level to prevent patient harm. For marketing authorization holders, manufacturers, and distributors.
• Active Pharmaceutical Ingredients (APIs) Supervision Supervision of API manufacturers for compliance with EU Directive 2011/62/EU requirements to prevent falsified medicinal products from entering the distribution chain. Supervisory activities started in 2016.
• GDP Supervision Good Distribution Practices monitoring of the entire distribution chain for medicinal products and APIs from manufacturer to patient. Includes periodic inspections of wholesalers, importers, and distributors.
• Medicine Shortage Notification Notification system for interruptions or terminations of medicinal products on the Dutch market, including a permission process for temporarily supplying medicines in different packaging. For marketing authorization holders and distributors.
• Pharmacovigilance (PhV) Inspection Science and activities relating to identification, assessment, understanding, and prevention of adverse effects and health problems related to medicinal product use. Includes risk assessment questionnaires and inspection programmes for MAHs.
• Medicines Without Marketing Authorization System for requesting permission to supply unregistered pharmaceutical products under Article 40 of the Dutch Medicines Act, including compassionate use and Doctor's Declaration pathways. For healthcare professionals and manufacturers.
• Illegal Trade in Medicines Monitoring Supervision and enforcement against illegal supply and trade in medicines, working with Customs, NVWA, and Public Prosecution Service. For enforcement authorities and supply chain participants.
• Medicine Advertising and Inducement Supervision Monitoring compliance with medicine advertising rules to prevent unwanted influence, including prohibition on advertising prescription medication to the public. Imposes administrative fines for violations. For pharmaceutical companies and advertisers.
• Medical Device Market Authorisation Oversight of market authorisation for medical devices and IVDs under European MDR and IVDR regulations, including supervision of notified bodies and CE certification. For medical device manufacturers, authorized representatives, and notified bodies.
• Medical Device Safety Notices Publication of Field Safety Notices about medical devices reported to the Inspectorate, including recalls and corrective actions for devices on the Dutch market. For healthcare providers, manufacturers, and the public.
• Post-Market Surveillance (PMS) Supervision Supervision of manufacturers' post-market surveillance activities to monitor safety and performance of medical devices after market launch, as required under European MDR/IVDR legislation. For medical device manufacturers.
• Vigilance and Incident Reporting System for reporting incidents and field safety corrective actions (FSCA) involving medical devices and IVDs, with mandatory reporting requirements for manufacturers. For medical device manufacturers, healthcare providers, and authorized representatives.
• Digital Care (eHealth) Supervision Supervision of eHealth applications including patient portals, medical apps, electronic patient records, and telemedicine. Includes both product safety and safe use assessment frameworks. For eHealth developers, healthcare providers, and digital health companies.
• National Authority for Containment (NAC) Monitoring of facilities containing poliovirus materials including Poliovirus Essential Facilities (PEFs). Includes audits using WHO methodology, certification application support, permit issuance advisory, and incident reporting requirements. For PEF facilities and poliovirus-handling organizations.

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

Partnerships

Ten partnerships are on record, tiered core and flagship.

• Dutch Healthcare Authority (NZa)coreOthersThe IGJ collaborates with the Dutch Healthcare Authority (NZa) as part of its inter-supervisory authority coordination. Both bodies work together to ensure comprehensive oversight of the healthcare sector in the Netherlands.
• National Institute for Public Health and the Environment (RIVM)coreOthersThe IGJ works closely with RIVM's Centre for Infectious Disease Control on polio reporting and containment matters. The RIVM serves as the technical arm for infectious disease surveillance and control that supports IGJ's supervisory activities.
• Netherlands Authority for Consumers & Markets (ACM)coreOthersThe IGJ cooperates with ACM in monitoring the healthcare market. ACM focuses on competition and consumer protection while IGJ focuses on quality and safety, creating complementary oversight.
• Central Information Unit on Healthcare Professions (CIBG)coreOthersThe CIBG serves as the competent authority for registration of economic operators in EUDAMED and issuance of export certificates. IGJ relies on CIBG data for manufacturer registration verification.
• Public Prosecution Service (OM)coreOthersThe IGJ refers criminal cases involving healthcare fraud, such as fraud in the production of medications, to the Public Prosecution Service. OM also provides sensitive data to IGJ for supervisory purposes.
• World Health Organization (WHO)flagshipOthersThe National Authority for Containment (NAC), part of IGJ, works under WHO's Global Action Plan for Poliovirus Containment (GAPIV). The NAC applies for WHO certificates for facilities meeting containment requirements and follows WHO audit methodology.
• European Medicines Agency (EMA)flagshipOthersThe IGJ works with EMA on centrally authorized products, including coordinating GMP inspections outside Europe through the CHMP committee. EMA also submits inspection requests to IGJ for centrally registered products.
• Medicines Evaluation Board (MEB/CBG)coreOthersThe MEB (CBG in Dutch) is the national competent authority for pharmacovigilance coordination in the Netherlands. IGJ and MEB collaborate on quality defect reports and medicine safety monitoring.
• Other EU Member State Inspection AuthoritiescoreOthersIGJ works closely with inspection authorities from other EU member states on joint GMP inspections and mutual recognition of inspection outcomes across the EEA.
• European Commission and MDCGcoreOthersThe European Commission and Medical Device Coordination Group (MDCG) are closely involved in the designation process for Dutch notified bodies under MDR and IVDR, and must issue positive opinions before designation.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Agence nationale de sécurité du médicament (ANSM): France's national medicines and medical devices safety agency. Comparable to IGJ in scope, covering medicines authorization, GMP inspections, pharmacovigilance, and medical device vigilance within a national regulatory framework.
• Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM): Germany's federal regulator for medicinal products and medical devices. Directly comparable to IGJ in supervising pharmaceutical manufacturing compliance, medical device market surveillance, and coordinating with EMA and EU member-state authorities.
• Swissmedic: Swiss national therapeutic products authority responsible for medicinal product authorization, medical device market surveillance, and GMP inspections. Comparable to IGJ in mandate and in operating as a non-EU national regulator with mutual recognition arrangements.
• Agenzia Italiana del Farmaco (AIFA): Italy's national drug regulator with responsibility for pharmaceutical regulation, GMP/GDP supervision, and pharmacovigilance. Directly comparable to IGJ as another EU member-state medicines authority operating within the same EMA-coordinated network.
• Medicines and Healthcare products Regulatory Agency (MHRA): UK national regulator responsible for medicines, medical devices, and blood components. Closely comparable to IGJ in mandate (GMP, GDP, pharmacovigilance, medical device oversight) and post-Brexit has become a parallel EEA-external authority that Dutch firms interact with for UK market access.

Regional players

• Health Canada: Canadian federal health agency responsible for pharmaceutical and medical device regulation. Comparable scope to IGJ in medicines and device oversight, but operates under a different jurisdiction with its own regulatory framework.
• Therapeutic Goods Administration (TGA): Australia's therapeutic goods regulator. Operates a comparable mandate (medicines, medical devices, GMP) but serves a different geographic market. Functions as a peer authority for mutual recognition discussions and reference comparison.
• Pharmaceuticals and Medical Devices Agency (PMDA): Japan's regulatory agency for pharmaceuticals and medical devices. Comparable to IGJ in GMP inspection, pharmacovigilance, and medical device review functions, but operates in a distinct geographic and regulatory environment.

Broad incumbents

• European Medicines Agency (EMA): EU-level agency coordinating the evaluation and supervision of medicines. While EMA operates supra-nationally rather than nationally, it is a core partner of IGJ — submitting GMP inspection requests and coordinating oversight of centrally authorized products.
• U.S. Food and Drug Administration (FDA): Largest and most globally influential health products regulator. While broader in scope and jurisdiction than IGJ, FDA performs analogous functions (GMP inspections, medical device clearance, pharmacovigilance) and serves as a benchmark for national regulatory frameworks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/health-youth-care-inspectorate

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about health youth care inspectorate